For adults struggling with weight, a weekly injection of tirzepatide offers real hope. Recent findings presented at the ...

The dosage range of tirzepatide is 2.5mg to 15mg, taken once weekly as a subcutaneous injection. Tirzepatide has the highest ...

Tirzepatide was associated with better glycemic control and weight loss outcomes than semaglutide and insulin among patients with T2D.

New research shows that people who take the weight-loss drug tirzepatide can keep most of the weight off for at least three ...

Medication doses were gradually increased to 15 mg for tirzepatide or 4.5 mg for dulaglutide, or to the highest maximum dose a participant could tolerate. The study’s primary and secondary ...

Among participants treated with tirzepatide 15 mg (N=224), 73%, 20%, and 7% experienced less than 5%, 5% to 10%, and 10% or more weight regain from nadir to Week 176, respectively. The authors ...

The original SURMOUNT-1 trial was published in NEJM in 2022, and found that, across 72 weeks, participants with obesity treated with 5 mg, 10 mg, or 15 mg of tirzepatide once weekly experienced ...

Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both ...

In the 731-patient SUMMIT study, participants were randomly assigned to either tirzepatide at a dose of between 2.5mg and 15mg per week or placebo, on top of their current heart failure treatment.

Patients with poorly controlled type 2 diabetes despite being on dulaglutide had better outcomes if they switched to tirzepatide than if they upped their dulaglutide dose. In this randomized trial ...

INDIANAPOLIS – The way people are accessing GLP-1 medications Semaglutide and Tirzepatide is going to become very limited after the drugs were taken off the FDA’s shortage list. Hundreds of ...

Each participant received weekly doses of tirzepatide—either 5 mg, 10 mg, or 15 mg—for three years. At the end of this period, the results were impressive. On average, participants lost ...